Jinwu Financial News | According to the Nomura Research Report, the management of Minimally Invasive Healthcare (00853) recently announced its plan to repay convertible bonds (CB), while providing guidance for the 2024-2026 fiscal year. The outstanding CB is about US$448 million, and the company issued a new CB of US$150 million to the management of Hillhouse Capital (Hillhouse Capital), the current convertible bondholder, at an annual interest rate of 5.75%; 2) US$300 million credit from financial institutions, and management believes that the interest rate will not be higher than 6%.
The bank believes that the situation may improve in the short term, but it will still be difficult in the long run. As a result, the target price for minimally invasive medicine was lowered from HK$7.19 to HK$6.71, giving it a “neutral” rating.